Engineered T Cells Show Promise Against Cancer & Autoimmune Disease
- A new approach to CAR-T cell therapy is showing promise, effectively destroying cancer cells in laboratory mice without the significant immune suppression often associated with current treatments.
- Conventional CAR-T cell therapy, a groundbreaking treatment for certain blood cancers, involves genetically modifying a patient’s own T cells to recognize and destroy cancer cells.
- Instead of targeting CD19, it targets B cell receptors carrying the IGHV4-34 gene.
A new approach to CAR-T cell therapy is showing promise, effectively destroying cancer cells in laboratory mice without the significant immune suppression often associated with current treatments. Developed by researchers at the University of Pennsylvania and QIMR Berghofer Medical Research Institute, this next-generation therapy, dubbed CART4-34, targets a specific gene found in high concentrations in cancerous B cells, offering a more precise attack and potentially opening doors to treating autoimmune diseases like lupus.
Beyond CD19: A More Targeted Approach
Conventional CAR-T cell therapy, a groundbreaking treatment for certain blood cancers, involves genetically modifying a patient’s own T cells to recognize and destroy cancer cells. These modified T cells are equipped with chimeric antigen receptors (CARs) that bind to specific antigens on the surface of cancer cells. The most common target for these CARs has been the CD19 molecule, a protein found on most B cells, including cancerous ones. While effective, CD19 CAR-T therapy has a significant drawback: it eliminates all cells expressing CD19, leading to a broad suppression of the immune system. As Andrea Henden, a clinician–researcher at the QIMR Berghofer Medical Research Institute in Brisbane, Australia, explains, “If you’re lucky enough to get a cure for your lymphoma, the most likely other threat to your health is through infection.” This immunosuppression represents a “fundamental problem” with current CAR-T cell treatments.
CART4-34 represents a shift towards greater precision. Instead of targeting CD19, it targets B cell receptors carrying the IGHV4-34 gene. This gene is thought to play a role in immune responses and is found at high levels in cancerous B cells, specifically in diffuse large B cell lymphoma, as demonstrated in genetically modified mice. Crucially, the IGHV4-34 gene is rarely found in healthy cells, meaning the therapy is less likely to attack non-cancerous tissue and suppress the broader immune system.
In trials with genetically modified mice, CART4-34 proved as effective as CD19 CAR-T therapy in destroying cancer cells, but without the same level of immune suppression. This selective targeting is a key advantage, potentially reducing the risk of opportunistic infections that can plague patients recovering from CD19 CAR-T therapy.
Potential for Autoimmune Disease Treatment
The implications of CART4-34 extend beyond cancer treatment. Researchers are exploring its potential application in autoimmune diseases, where the immune system mistakenly attacks the body’s own tissues. The presence of antibodies targeting cells carrying IGHV4-34 is common in individuals with lupus, and these antibodies are often associated with more severe forms of the disease. Marco Ruella, a clinician–researcher at the University of Pennsylvania, whose team developed CART4-34, notes this connection, suggesting the engineered T cells could selectively eliminate the autoreactive B cells driving the disease process.
This potential application builds on a growing body of research into engineered T cell immunotherapy for a range of non-oncological diseases. A review published in February 2025 highlights recent advances in engineering T cells for autoimmune and inflammatory diseases, infections, fibrosis, hemophilia, and even aging. The field is rapidly expanding, with researchers exploring ways to harness the power of engineered T cells to modulate the immune system in a variety of therapeutic contexts.
Expanding the Toolkit: Bispecific and Multispecific T-Cell Engagers
Alongside advancements in CAR-T cell technology, other approaches to engineered T cell therapies are also gaining traction. Bispecific and multispecific T-cell engagers (TCEs) are designed to enhance immune modulation and deliver more targeted therapies. These TCEs aim to improve patient outcomes and quality of life across a diverse range of diseases, including cancer and autoimmune conditions.
The Future of Engineered T Cells
While CART4-34 and other engineered T cell therapies show significant promise, further clinical investigation is needed to fully realize their therapeutic potential. The review published in emphasizes that broader therapeutic applications require more extensive clinical trials. However, the development of more targeted therapies like CART4-34 represents a crucial step forward in overcoming the limitations of current CAR-T cell treatments and expanding the reach of this powerful immunotherapy to a wider range of diseases.
Recent research also points to the development of “off-the-shelf” immunotherapies, utilizing engineered invariant natural killer T cells (NKT cells) capable of infiltrating solid tumors. A study published on , systematically compared four targeting strategies for these NKT cells, suggesting a potential pathway for readily available, pre-manufactured immunotherapies.